These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21146988)

  • 1. Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
    Manning DD; Cioffi CL; Usyatinsky A; Fitzpatrick K; Masih L; Guo C; Zhang Z; Choo SH; Sikkander MI; Ryan KN; Naginskaya J; Hassler C; Dobritsa S; Wierschke JD; Earley WG; Butler AS; Brady CA; Barnes NM; Cohen ML; Guzzo PR
    Bioorg Med Chem Lett; 2011 Jan; 21(1):58-61. PubMed ID: 21146988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of diazepinone-based 5-HT3 receptor partial agonists.
    Manning DD; Guo C; Zhang Z; Ryan KN; Naginskaya J; Choo SH; Masih L; Earley WG; Wierschke JD; Newman AS; Brady CA; Barnes NM; Guzzo PR
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2578-81. PubMed ID: 24755431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
    Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Minato K; Sato M
    J Med Chem; 2010 Nov; 53(21):7549-63. PubMed ID: 20931963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally active benzoxazole derivative as 5-HT3 receptor partial agonist for treatment of diarrhea-predominant irritable bowel syndrome.
    Yoshida S; Shiokawa S; Kawano K; Ito T; Murakami H; Suzuki H; Sato Y
    J Med Chem; 2005 Nov; 48(22):7075-9. PubMed ID: 16250667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological properties of 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(quinolin-2-yl)piperazin-1-yl]butyl]quinazolin-4(3H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an experimental IBS model.
    Tamaoki S; Yamauchi Y; Nakano Y; Sakano S; Asagarasu A; Sato M
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1315-23. PubMed ID: 17540858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSTI-300 (SMP-100); a Novel 5-HT
    Roberts A; Grafton G; Powell AD; Brock K; Chen C; Xie D; Huang J; Liu S; Cooper AJ; Brady CA; Qureshi O; Stamataki Z; Manning DD; Moore NA; Sargent BJ; Guzzo PR; Barnes NM
    J Pharmacol Exp Ther; 2020 Apr; 373(1):122-134. PubMed ID: 32102919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome.
    Spiller RC
    Curr Opin Pharmacol; 2011 Feb; 11(1):68-74. PubMed ID: 21398180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.
    Meyers NL; Hickling RI
    Drugs R D; 2008; 9(1):37-63. PubMed ID: 18095752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT(3) receptors: potential of individual isoforms for personalised therapy.
    Niesler B
    Curr Opin Pharmacol; 2011 Feb; 11(1):81-6. PubMed ID: 21345729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
    Johanson JF
    Neurogastroenterol Motil; 2004 Dec; 16(6):701-11. PubMed ID: 15601419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.
    Yang Z; Fairfax DJ; Maeng JH; Masih L; Usyatinsky A; Hassler C; Isaacson S; Fitzpatrick K; DeOrazio RJ; Chen J; Harding JP; Isherwood M; Dobritsa S; Christensen KL; Wierschke JD; Bliss BI; Peterson LH; Beer CM; Cioffi C; Lynch M; Rennells WM; Richards JJ; Rust T; Khmelnitsky YL; Cohen ML; Manning DD
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6538-41. PubMed ID: 20889341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
    Salaga M; Binienda A; Tichkule RB; Thakur GA; Makriyannis A; Storr M; Fichna J
    Eur J Pharmacol; 2018 Oct; 836():34-43. PubMed ID: 30121173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial agonism of 5-HT3 receptors: a novel approach to the symptomatic treatment of IBS-D.
    Moore NA; Sargent BJ; Manning DD; Guzzo PR
    ACS Chem Neurosci; 2013 Jan; 4(1):43-7. PubMed ID: 23342199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
    Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
    J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Chloroindole: a potent allosteric modulator of the 5-HT₃ receptor.
    Newman AS; Batis N; Grafton G; Caputo F; Brady CA; Lambert JJ; Peters JA; Gordon J; Brain KL; Powell AD; Barnes NM
    Br J Pharmacol; 2013 Jul; 169(6):1228-38. PubMed ID: 23594147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; Boznańska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome.
    Ren TH; Wu J; Yew D; Ziea E; Lao L; Leung WK; Berman B; Hu PJ; Sung JJ
    Am J Physiol Gastrointest Liver Physiol; 2007 Mar; 292(3):G849-56. PubMed ID: 17110521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy for irritable bowel syndrome.
    Olden KW
    N Engl J Med; 2004 Mar; 350(12):1261-3; author reply 1261-3. PubMed ID: 15028836
    [No Abstract]   [Full Text] [Related]  

  • 19. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome.
    Zou BC; Dong L; Wang Y; Wang SH; Cao MB
    Chin Med J (Engl); 2007 Dec; 120(23):2069-74. PubMed ID: 18167178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonergic agents and the irritable bowel syndrome: what goes wrong?
    Spiller R
    Curr Opin Pharmacol; 2008 Dec; 8(6):709-14. PubMed ID: 18672092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.